{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T07:20:24Z","timestamp":1762068024095,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":413,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13311-022-01307-7","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T15:02:37Z","timestamp":1664377357000},"page":"1047-1049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Evolving Landscape of Motor Neuron Disease Therapeutics"],"prefix":"10.1016","volume":"19","author":[{"given":"Nicholas J.","family":"Maragakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2001-8470","authenticated-orcid":false,"given":"Jeffrey D.","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib1","first-page":"4","article-title":"Nuclear pore dysfunction in neurodegeneration","volume":"19","author":"Spead","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib2","first-page":"4","article-title":"Emerging therapies and novel targets for TDP-43 proteinopathy in ALS\/FTD","volume":"19","author":"Hayes","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib3","first-page":"4","article-title":"Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis","volume":"19","author":"Li","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib4","first-page":"4","article-title":"Altered bioenergetics and metabolic homeostasis in amyotrophic lateral sclerosis","volume":"19","author":"Nelson","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1007\/s13311-022-01307-7_bib5","first-page":"4","article-title":"Pathogenic extracellular vesicle (EV) signaling in amyotrophic lateral sclerosis (ALS)","volume":"19","author":"Kim","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib6","first-page":"4","article-title":"Axon Biology in ALS: mechanisms of axon degeneration and prospects for therapy","volume":"19","author":"Coleman","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib7","first-page":"4","article-title":"Antisense oligonucleotides for the study and treatment of ALS","volume":"19","author":"Boros","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib8","first-page":"4","article-title":"Approaches to gene modulation therapy for ALS","volume":"19","author":"Meijboom","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"-","key":"10.1007\/s13311-022-01307-7_bib9","first-page":"4","article-title":"Considerations for ALS clinical trial design","volume":"19","author":"Fournier","year":"2022","journal-title":"Neurotherapeutics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-022-01307-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-022-01307-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:47:35Z","timestamp":1761806855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1878747923010668"],"URL":"https:\/\/doi.org\/10.1007\/s13311-022-01307-7","relation":{},"ISSN":["1878-7479"],"issn-type":[{"type":"print","value":"1878-7479"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Landscape of Motor Neuron Disease Therapeutics","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-022-01307-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}